D
espite early detection and state-of-the art therapeutic approaches for thoracic malignancies, development of radiation-induced cardiomyopathy can offset the promising benefits of radiotherapy. Currently, there are no specific therapeutic agents that are known to antagonize these effects. Radiation is the main trigger for the subsequent inflammation, fibrosis, and cardiomyocyte loss leading to the development of myocardial dysfunction.
1,2 A dose-dependent relationship between radiation exposure and subsequent cardiac mortality was initially reported in a study cohort from Stockholm County in Sweden. 3 Compared with nonirradiated patients, patients who had undergone chest radiotherapy had increased risk. 4 The existing therapy for radiation-induced cardiomyopathy is driven by conventional therapies developed for patients with other forms of cardiomyopathies. In recent years, there has been emphasis on exposing the patient to as little radiation as possible. 5 Despite these dose-limiting techniques, common cancers, including breast, lungs, and gastrointestinal cancers, need significant radiation dose, and patients are at risk of developing both acute and long-term effects of radiation exposure to the heart. In search of novel therapeutic agents, we assessed the therapeutic potential of a novel tetrapeptide, N-acetyl-Ser-Asp-Lys-Pro (Ac-SDKP). Ac-SDKP was discovered by Lenfant et al 6 as a ubiquitous endogenous peptide. The precursor of Ac-SDKP is thymosin-β4, which is essential for tissue healing and cell differentiation. 6, 7 Our previous studies in cardiac fibroblasts, 8 as well as in 2 transgenic rat models of cardiac fibrosis, have shown strong antifibrotic effects of Ac-SDKP. [9] [10] [11] Ac-SDKP was also shown to have macrophage inhibitory effects in preclinical models. 12 In particular, Ac-SDKP was shown to inhibit the expression and activity of a carbohydrate-binding surface protein, Mac-2 (galectin-3) expressed by macrophages. 9, 11 We have previously shown an association between Mac-2 expression and cardiac fibrosis and heart failure in preclinical models and patients. 13, 14 Here, we report a novel therapeutic approach to reduce the detrimental effects of radiation-induced cardiotoxicity. We have used a rat model of radiationinduced cardiomyopathy, which shows cardiomyocyte apoptosis, increased extracellular matrix, macrophage infiltration, and Mac-2 expression. We also report that treatment with a small peptide, Ac-SDKP limits the fibroinflammatory cascade triggered by radiation exposure, specifically involving macrophage activity. The results of this study demonstrate strong therapeutic promise, which can potentially benefit large number of cancer survivors.
METHODS
The data that support the findings of this study are available from the corresponding author on reasonable request.
Rat Model of Cardiac Irradiation
We first optimized radiation dose using current dosimetry data obtained by radiation physicists at Roswell Park Cancer Institute. Rats received experimental radiation with 250 kV photons into the left hemithorax with a 1-cm cone and 2-mm thick lead plates to limit radiation exposure to the surrounding tissues. Anesthetized (isoflurane 4% induction, 2% maintenance) 10-to 12-week-old male and female Sprague Dawley rats (Envigo) received a single dose of 30 Gray (Gy) radiation or sham therapy into the left hemithorax using an orthovoltage radiator (Philips, Best, the Netherlands). Rats were observed during radiation exposure and for 30 minutes into recovery. The animal care and experimental protocols followed the US National Institutes of Health guidelines and were approved by the Institutional Animal Care and Use Committees of the Roswell Park Cancer Institute at Buffalo, NY.
Ac-SDKP Synthesis and Delivery
Ac-SDKP was synthesized using fluorenylmethyloxycarbonyl solid phase peptide synthesis (Genescript, Piscataway, NJ). Based on prior studies from our group 10 and others, [15] [16] [17] we
WHAT IS NEW?
• The most common thoracic malignancies are treated with ionization radiation. Because ionization radiation is responsible for early and delayed cardiac damage, there is an urgent need to identify novel therapeutic strategies to mitigate these effects.
• This article reports a preclinical study that examines the anti-inflammatory and antifibrotic effects of a small peptide, Ac-SDKP, in a rodent model of thoracic ionization radiation exposure. Chronic Ac-SDKP infusion inhibits macrophage activity, reduces cardiac fibrosis, and preserves myocardial contractile forces.
WHAT ARE THE CLINICAL IMPLICATIONS?
• We anticipate that this study will have important therapeutic implications to inhibit radiationinduced cardiotoxicity, thus benefitting a large cohort of thoracic cancer survivors treated with ionization radiation. • In the future, the protective effects of Ac-SDKP can be extended to benefit larger groups, including survivors of nonthoracic cancers, in which postradiation morbidity remains high.
• Because Ac-SDKP is an endogenous peptide, concerns for the potential peptide-related toxicities, including immune compromise, are greatly reduced.
determined that a dose of 3.2 mg/kg per day Ac-SDKP was required to reach maximal therapeutic effects. To continuously infuse Ac-SDKP at this rate, the purified peptide was delivered subcutaneously in a continuous manner by surgical implantation of Alzet mini-osmotic pumps. All procedures were performed in sterile manner under anesthesia, and analgesia was achieved with buprenorphine (0.05 mg/kg SC).
Ac-SDKP Safety Protocol
We first tested the clinical and hematologic safety profile of Ac-SDKP in a smaller group of rats (n=5). These rats received identical doses of Ac-SDKP therapy for 4 weeks as other experimental groups. Complete blood count was performed at baseline and 1 month after radiation in rats with and without Ac-SDKP treatment. Rats were monitored daily for overall health and any skin irritation at the radiation site, and body weight was monitored biweekly.
Ac-SDKP Therapy Protocol
We used 3 experimental groups: (1) age-matched normal Sprague Dawley rats (n=12); (2) rats that received thoracic radiation (n=15); and (3) Ac-SDKP therapy group that received thoracic radiation followed by 18 weeks of subcutaneous Ac-SDKP (3.2 mg/kg per day) infusion (therapy initiated within 24 hours of ionization radiation exposure). To minimize discomfort, all interventions were performed on anesthetized animals. Euthanasia procedure conformed to the guidelines from the Panel on Euthanasia of the American Veterinary Medical Association.
Cardiac Magnetic Resonance Imaging
We used 4.7-Tesla preclinical magnetic resonance imaging (MRI)scanner using a 72-mm ID, quadrature transceiver coil, and the ParaVision 3.0.2 acquisition platform (Bruker Biospin, Billerica, MA). Rats were anesthetized and maintained with 2% to 2.5% isoflurane during the duration of the imaging session. Body temperature and vital signs were maintained with a magnetic resonance-compatible gating and monitoring system (model 1025, SA Instruments, Stony Brook, NY). A detailed explanation for the MRI measurements of cardiac volumes, function, velocities, and dynamic contrast imaging has been outlined in the Data Supplement.
Immunohistochemistry and Tissue Morphometry
Macrophages were stained using a rat-specific anti-CD68 antibody (Abcam, Cambridge, MA; Ab-31630). The immunohistochemical studies were performed at the Roswell Park Cancer Institute pathology resource core-laboratory. Considering the patchy distribution of inflammation, images were obtained from the pericardial half of each section that included an average of 10 images from alternate microscopic field in a clock-wise fashion to cover the larger representative area of the myocardium. Mononuclear inflammatory cells with cytoplasmic staining were counted. The extent of myocardial fibrosis was visualized by trichrome staining. For a systematic image acquisition, the total myocardial area and the area of positive staining for fibrosis were quantified using National Institute of Health imaging software (National Institute of Health, Bethesda, MD).
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Terminal Deoxynucleotidyl Transferase dUTP Nick-End Labeling Staining for Apoptosis Detection
Terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay was performed using S7101 ApopTag Plus Peroxidase in Situ Apoptosis Kit (Millipore Sigma, Burlington, MA). Briefly, 4 µm formalin-fixed paraffin sections were treated with 0.3% hydrogen peroxide for 10 minutes. After digestion with 20 µg/mL proteinase-K for 17 minutes, slides were incubated with terminal deoxynucleotidyl transferase enzyme for 75 minutes. After stepwise antidigoxigenin-peroxidase and DAB chromogen (Dako, Santa Clara, CA; K3468) treatment, slides were counterstained with hematoxylin and examined under the microscope. Pyknotic myocyte nuclei with homogenous brown nuclear staining were counted in average of 10 randomly acquired images per tissue section as described above. The investigator was blinded to the experimental group during image acquisition and analyses.
Cardiomyocyte Nuclear Density
Myocyte nuclear density was assessed in the transverse sections of the trichrome-stained sections, using a cell quantification protocol reported previously.
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Cell Imaging Studies
To examine the uptake of Ac-SDKP into the macrophages, we first performed in vitro cell imaging studies using Ac-SDKPfluorescein isothiocyanate (FITC) agent.
Fluorophore-Conjugated Ac-SDKP and Scrambled Peptide (Ac-KDPS) Synthesis
The FITC-conjugated Ac-SDKP was synthesized using fluorenylmethyloxycarbonyl solid phase peptide synthesis (Genescript, Piscataway, NJ), and FITC-conjugated Ac-KDPS was synthesized using similar fluorenylmethyloxycarbonyl synthesis protocol (Lifetein, Somerset, NJ).
Ac-SDKP Cytochemistry, Confocal Microscopy, and Fluorescence-Activated Cell Sorting Analysis
For these studies, cultured macrophages (RAW 264.7 cells, ATCC) were incubated with FITC-labeled Ac-SDKP or scrambled peptides (0.05, 0.1, 0.2, 0.5 µmol/L). For uptake studies, cells were detached and analyzed with a BD LSR Fortessa flow cytometer. For peptide localization assays, cells were cultured on sterile cover slips, fixed with 4% paraformaldehyde, mounted and imaged using a confocal microscope (ZEISS LSM 800 Laser scanning microscope) at ×6300 magnification.
Enzyme-Linked Immunosorbent Assays
Cellular Mac-2 Levels
We used an indirect cell-directed ELISA for the determination of radiation-induced Mac-2 expression by cultured macrophages (RAW 264.7 cell lines; LS-F2009, Lifespan Biosciences, Seattle, WA). Cultured macrophages were exposed to 9 Gy of radiation using a specialized orthovoltage radiation chamber and incubated for 24 hours. Subsequent Mac-2 expression by these cells was measured using anti-Mac-2 primary antibody per manufacturer's recommendations.
Myocardial Mac-2 Levels
The myocardial Mac-2 protein levels were measured using rat-specific horseradish peroxidase-dependent Mac-2 ELISA kit (ERLGALS3, Thermo Fisher Scientific, Waltham, MA). Myocardial tissue samples were homogenized in PBS, centrifuged, and protein concentrations were measured. Standard curves were generated using the known concentration of recombinant Mac-2 protein. The Mac-2 concentration was quantified based on the optical densities measured at 490 nm and normalized to tissue protein concentrations.
Cardiac Fibroblast Isolation and RealTime Polymerase Chain Reaction for Collagen and TGF-β1 Expression
To examine the effects of radiation on collagen synthesis, we isolated cardiac fibroblasts from 8-to 12-week-old Mac-2 +/+ and Mac −/− C57/BL6J mice (Jackson lab). We performed real-time polymerase chain reaction for collagen I, III, and TGF-β1 (transforming growth factor β1) expression after in vitro radiation exposure using the cardiac fibroblasts isolated from Mac-2 −/− mice and wild-type controls (Mac-2 +/+ ). A detailed protocol for cell isolation and real-time polymerase chain reaction and primer information has been outlined in the Data Supplement.
Statistical Analyses
Quantitative end points were summarized by group using the mean and SEM. When appropriate, the end points were modeled as a function of treatment group (control, radiation alone, and radiation+Ac-SDKP) using 1-way ANOVA models; with between-group comparisons made using Holm-Bonferroni-adjusted post hoc tests. End point comparisons between Mac-2 +/+ and Mac-2 −/− mice were made using unpaired t tests. The association between cellular uptake and Ac-SDKP peptide concentration was evaluated using the Spearman correlation coefficient. All model/test assumptions were verified graphically using quantile-quantile and residual plots, with transformations applied as appropriate. All tests were 2 sided at a nominal significance level of 0.05; that is, P<0.05 was considered significant.
RESULTS
Changes in Cardiac Morphology and Function Quantified by Cardiac MRI
We used newly developed MRI protocols to objectively assess cardiac function and extracellular matrix in our model.
Extracellular Matrix Volume
We compared the extracellular matrix by dynamic contrast imaging. Compared with baseline controls, radiation exposure led to delayed contrast clearance (reduced signal decay) and thus was consistent with increased myocardial extracellular matrix volume. Treatment with Ac-SDKP significantly improved the delayed contrast clearance dynamics as shown in Figure 1A , which is consistent with less myocardial extracellular matrix (signal decay/min: control, −7.4±1.0; radiation, −4.7±0.7; and radiation+Ac-SDKP, −7.5±0.6; P=0.03 radiation versus radiation+Ac-SDKP).
Left Ventricular (LV) Volume and Function
Cardiac MRI with quantitative volumetric data analysis showed no significant differences in the LV ejection fraction or fractional shortening. The stroke volumes and LV systolic and diastolic dimensions remained normal for all groups, with neither radiation exposure nor Ac-SDKP therapy showing significant changes (Table II in the Data Supplement). 
Myocardial Contractile/Relaxation Velocities
The baseline control rats had a mean early-systolic velocity of −2.5±0.4 cm/s and early-diastolic velocity of 3.5±0.6 cm/s. Rats with radiation exposure showed significantly reduced early systolic (contractile) and early diastolic (relaxation) velocities. Ac-SDKP therapy improved the radial contractility both during systole and diastole as shown in Figure 1B and 1C.
Density and Distribution of Myocardial Collagen Tissue
We performed quantitative imaging of cardiac collagen content from Masson trichrome-stained tissue sections. Radiation exposure led to a patchy myocardial fibrosis more pronounced in the anterior wall. As shown in Figure 2 , this increase in interstitial collagen was significantly inhibited by Ac-SDKP therapy (% fibrosis: control, 4.0±0.4; radiation, 9.3±0.8; radiation+Ac-SDKP, 4.9±0.8; P=0.004 radiation versus radiation+Ac-SDKP; n=8-10).
Presence of DNA Degenerative Changes and Cardiomyocyte Loss
Increased number of TUNEL-positive cells were identified in rats after thoracic radiation exposure (control, 1.3±0.2, and radiation 4.4±0.4, P<0.001). Ac-SDKP therapy significantly decreased the number of TUNEL-positive cells (1.9±0.4, P<0.001 versus radiation; Figure 3 ). Numeric density of cardiomyocytes nuclei was identified in each cross-sectional image captured at high magnification. Connective tissue staining was subtracted from the total tissue area to determine the percentage that was represented by myocytes (% myocyte area). There was significant decrease in the nuclear density in radiation exposed rats compared with control (nuclei/high power field: control, 175±15, radiation, 116±5, P<0.001). Ac-SDKP therapy prevented the myocyte nuclear drop (145±6, P=0.01 versus radiation, n=8-10/group; Figure 4 ).
Examination of Macrophage Infiltration and Activity
Myocardial Macrophage Density
We examined the degree of myocardial inflammation by counting the number of CD68-positive cells after chest radiation. We identified CD68-positive cells at myocardial interstitial spaces (with the exclusion of CD68-positive cells in the intravascular space). Control rats showed a small number of CD68-positive cells, likely representing resident tissue macrophages. As demonstrated in Figure 5 , abundant CD68-positive cells were visualized in rats with radiation exposure, especially localized to the areas of patchy fibrotic changes. Ac-SDKP therapy significantly reduced CD68 cell infiltration to near-baseline levels (cells/high power field: control, 7±1; radiation, 24±5; radiation+Ac-SDKP, 11±1; P=0.008 radiation versus radiation+Ac-SDKP; n=8-10).
Myocardial Mac-2 Levels
We measured Mac-2 expression in the rat myocardium as a potential mediator of tissue fibrosis. Mac-2-specific ELISA on myocardial tissue homogenates showed a significant increase of Mac-2 levels after radiation exposure ( Figure 6A ). Ac-SDKP therapy significantly reduced the myocardial Mac-2 expression (control, 14±8; radiation, 85±15; radiation+Ac-SDKP, 36±9; P=0.01 radiation versus radiation+Ac-SDKP; n=8-10 per group).
Mac-2 Release From the Radiation-Exposed Macrophages
To determine the macrophage response to ionizing radiation and the effects of Ac-SDKP therapy, we measured Mac-2 levels in cultured macrophages with and without Ac-SDKP treatment. Macrophage-specific cell-cytokine ELISA was used to quantify radiation-induced Mac-2 expression. We found that exposure to 9 Gy radiation significantly increased the expression of Mac-2 protein by cultured macrophages within 24 hours, which was significantly inhibited by Ac-SDKP at 10 µmol/L (control, 1.5±0.1; radiation, 2.2±0.1; radiation+Ac-SDKP, 1.9±0.1; P=0.01 radiation versus radiation+Ac-SDKP; n=8 per group; Figure 6B ).
Ac-SDKP Uptake by Cultured Macrophages
Confocal microscopy with 3-dimensional data processing demonstrated a robust uptake of FITC-Ac-SDKP into the cultured macrophages. The FITC-Ac-SDKP (0.5 μmol/L) was localized into the perinuclear region within 4 hours ( Figure 7A-7C) . The FITC-conjugated scrambled peptide used as control showed weak and diffuse intracellular staining ( Figure 7D-7F ). In addition, our fluorescence-activated cell sorting analysis to quantify the percentage of FITC-Ac-SDKP-positive macrophages showed dose-dependent uptake of FITC-Ac-SDKP by macrophages (R s =0.92; P<0.001) at the peptide concentration ranging from 0.05 µmol/L (10%±2%) to 0.5 µmol/L (33%±1%; Figure 7I ). Compared with FITC-Ac-SDKP, the FITC-conjugated scrambled peptide was taken up by smaller percentage of cultured macrophages ( Figure 7G and 7H) . 
Cardiac Fibroblast Response to Radiation After Mac-2 Gene Deletion
To further investigate the profibrotic effects of Mac-2 in radiation-induced cardiac fibrosis, we compared the radiation-induced profibrotic response in cardiac fibroblasts isolated from Mac-2 −/− mice and wild-type controls (Mac-2 +/+ (Figure 8A-8C) . The expression of TGFβ1 mRNA in the rat myocardium was measured in the heart specimens obtained at 18 weeks after radiation. We found no significant differences in the expression of cardiac TGFβ1 mRNA at the later stage (18 weeks) after radiation exposure ( Figure 8D ).
Safety Profile of Ac-SDKP Therapy
We performed initial in vivo study to examine the safety of Ac-SDKP in immune system. Importantly, there was no evidence of untoward effects or any physical evidence of immune suppression after chest radiation with and without Ac-SDKP. There was a trend toward the reduction of lymphocyte count in radiated rats (P=NS), which was compensated by an increase in the number of monocytes (baseline, 3.2%±0.4%; radiation, 4.2%±0.2%; P=0.05). Although platelet counts were significantly decreased post-radiation (Table III in the Data Supplement) , Ac-SDKP therapy did not change platelets or white cell counts compared with the radiation group.
DISCUSSION
Radiation-induced cardiomyopathy is a long-term side effect of radiotherapy of intrathoracic, chest wall, and breast tumors when radiation field involves all or part of the heart. 20 There is a growing need for an effective and nontoxic pharmacological agent that could counter these effects. Here, we identified a novel role for Ac-SDKP to inhibit the detrimental effects of radiation exposure to the heart. Previously, we have demonstrated that administration of Mac-2 directly into the heart causes myocardial fibrosis and loss of cardiac function. 9, 13 In this study, Ac-SDKP has shown anti-inflammatory, antifibrotic, cardiomyocyte preserving, and Mac-2 inhibitory effects in rat model of heart radiation. For the first time, we demonstrate that Ac-SDKP enters into the macrophages and inhibits their activation and Mac-2 expres- sion in response to radiation. Importantly, Mac-2 deletion abrogates radiation-induced collagen and TGF-β1 mRNA expression, highlighting an important role for Mac-2 in the pathogenesis of radiation-induced heart disease.
Radiation-Induced Cardiac Fibrosis: Virtuous Intentions, Malign Consequences?
Radiation-induced cardiac complications are related to total radiation dose, younger age at the exposure, a greater time elapsed since exposure, and concomitant use of cardiotoxic chemotherapeutic agents. 21 A seminal study by Kiscsatári et al 22 compared the effects of heart radiations at different doses. They demonstrated that cardiac radiation of 20 to 40 Gy was well tolerated and caused no animal death. A higher dose (50 Gy) caused tachypnea, early cardiac functional decline, cardiac arrhythmias, and death. 22 We also examined the biological safety profile of 30 Gy radiation in a subgroup of rats. We found that 30 Gy of radiation did Figure 6 . Mac-2 expression in myocardial tissue homogenate and cultured macrophages measured by ELISA. A, Mac-2 levels in myocardial tissue homogenate. Radiation exposure significantly increased myocardial Mac-2 levels, which was inhibited by N-acetyl-Ser-AspLys-Pro (Ac-SDKP). n=7 to 10, *P=0.001 radiation vs control, †P=0.01 radiation vs radiation+Ac-SDKP. B, Mac-2 expression in cultured macrophages. Radiation exposure (9 Gy) significantly increased Mac-2 expression, which was inhibited by Ac-SDKP (10 µmol/L). n=8 per group, *P=0.001, radiation vs control; †P=0.02, radiation vs radiation+Ac-SDKP. not cause acute clinical and hematologic effects, and all the animals survived on this dose. Therefore, balancing the acute morbid radiation toxicity and death versus subacute or chronic cardiotoxicity, we used a radiation dose of 30 Gy.
Radiation-related myocardial fibrosis can be initially asymptomatic often leading to late diagnosis. 23 Histologically, it is characterized by thick collagen bands criss-crossing the cardiac tissue and separating and replacing cardiomyocytes. 24 Sridharan et al 25 studied brown Norway rats exposed to local heart radiation, in which inflammation and fibrosis were seen at 3 and 6 months after radiation, but most severe cardiac functional changes were seen 3 months after a single radiation dose of 24 Gy. The histomorphologic changes seen in our study are in agreement with the previously published data.
Prior Preclinical Studies With Therapeutic Emphasis
Treatment of radiation-induced heart disease currently consists of standard medical therapy. Prior studies have examined the antifibrotic effects of an antioxidant agent amifostine in rats. 26 However, amifostine is not currently used because of its side effects. In 2013, Sridharan et 27 reported the effects of pentoxifylline and tocotrienols in a rat model of radiation-induced cardiac disease. Pentoxifylline with and without tocotrienols did not alter increases in LV diastolic pressure or deposition of collagen although tocotreinols decreased LV macrophage and mast cell densities. Because the effects of cardiac and pulmonary injury often coexist after radiotherapy, angiotensin converting enzyme inhibition was thought to be a promising therapeutic target, but the initial enthusiasm was offset by its side effects involving bradykinin accumulation which causes debilitating cough, angioedema, and hypotension. 28 Clinically, it is difficult to discern whether the side effect of nonremitting cough is because of bradykinin accumulation, cancer progression, or pulmonary pathology. Based on its known mechanism of action, Ac-SDKP has no bradykinin-mediated side effects and also offers additional tissue healing and macrophages inhibitory effects, beyond the reported actions of angiotensin converting enzyme inhibitors.
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Cardiac MRI: 1-Stop Shop Under the Magnet
Majority of previous histological studies were performed in postmortem specimens, and cardiac function was characterized by conventional ultrasound technology. Recognizing the need for noninvasive imaging with superb spatial and temporal resolution and high reproducibly, we have used high-field cardiac MRI technique for myocardial morphological and functional assessments.
There are conflicting data in the literature on the effects of cardiac irradiation on overall global LV function. Studies have reported a wide array of results ranging from moderate reduction in ejection fraction, diastolic dysfunction, with some studies reporting supranormal LV contractility after radiation. 21, 30, 31 Recent developments in MRI technology have enabled accurate evaluation of cardiac function, as well as quantification of myocardial motion and deformation. Although volumetric methods examine the global cardiac function, myocardial velocities can provide additional information at the preclinical level with quantification of initial force generation at onset of systole or diastole. The effects are determined by elasticity, fiber structure, and myocardial geometry, 32 which are expected to be affected by ionizing radiation.
Ac-SDKP: A Novel Therapeutic Target
In line with our prior observations in genetic models of angiotensin converting enzyme overexpression and oth- Cardiac fibroblasts isolated from adult (wild type and Mac-2 knockout) mice were exposed to radiation (9 Gy) and incubated for 72 h in CO 2 incubator; mRNA was isolated and quantitative PCR was performed. Radiation exposure increased collagen I (A), collagen III (B), and TGFβ1 (C) gene expression in wild-type cardiac fibroblast but not in Mac-2 null cells. Data are expressed as fold change of control. n=3 each group, presented as a pooled mean of 2 independent experiments performed in duplicates. *P<0.001 wild-type vs KO (knock out) post-radiation. D, Chronic myocardial TGFβ1 mRNA expression levels in rat hearts on completion of in vivo studies, that is, after 18 wk of radiation. P=not significant. er models of cardiac injury, 11 we show strong antifibrotic and macrophage inhibitory effects of Ac-SDKP after localized heart radiation. In addition to these effects, we have, for the first time, demonstrated a cellular uptake of Ac-SDKP by cultured macrophages, which highlights the therapeutic relevance of this peptide after radiation exposure. The relevance of Ac-SDKP uptake around the nucleus can be reconciled to our prior observations that Ac-SDKP inhibited differentiation of bone marrow stem cells to macrophages and also inhibited macrophage migration, both effects that are likely mediated by proteins involved in nucleus-to-cytoplasmic shuttle, for example, TGF-β, Smad2/3, and Mac-2 activity. 10, 11 Ac-SDKP was initially thought to play an important role as a cytoprotective agent by keeping the bone marrow stem cells at the quiescent state during chemotherapy. 33, 34 The antifibrotic effects can similarly be explained by a possible cell cycle inhibitory effects of Ac-SDKP in cardiac fibroblasts. In fact, Kanasaki et al 35 reported the cyclin D1 inhibitory effects of Ac-SDKP. Despite the robust macrophage inhibitory effects of Ac-SDKP, we have found no evidence of Ac-SDKP-induced immune suppression in our experimental model.
Increased Mac-2 Activity: A Newly Emerging Mechanism of Cardiac Fibrosis
Mac-2 (galectin-3) is a β-galactoside-binding lectin of ≈30 kDa that has been implicated in inflammation and fibrosis. 13, 36 Identified first as an antigen on the surface of peritoneal macrophages, Mac-2 is the only chimera-type member of the galectin family. 37 Mac-2 plays a critical role in phagocytosis by macrophages when cross-linked by the Fcγ receptor. 36 Mac-2 is upregulated when monocytes differentiate into macrophages. 38 As shown in our earlier study, Mac-2 is a specific and highly upregulated marker of myocardial macrophages in failing hearts. 13 A recent study by Farrah et al 39 has shown reduced Mac-2 levels in response to endothelin antagonism. Increased Mac-2 expression has also been shown in a rat model of postradiation pulmonary fibrosis. 40 Previous research has also demonstrated a causative role of Mac-2 in hepatic fibrosis. 41 Evidence for this new role of Mac-2 in radiation-induced cardiac fibrosis comes from our Mac-2 null fibroblast studies. Lack of expression of collagen I and III gene expression in Mac-2 null cardiac fibroblasts exposed to radiation suggests a crucial role of Mac-2 for radiation-induced fibrogenesis.
The antifibrotic and Mac-2 inhibitory effects of Ac-SDKP were examined by Liu et al, 9 who reported that Ac-SDKP exerted anti-Mac-2 effects via the inhibition of Smad3 phosphorylation, which is an important transcription factor for collagen synthesis. TGFβ plays a central role in organ fibrosis, particularly radiation-induced fibrosis. Previous studies have shown increase in TGFβ in the heart after radiation exposure. Prior studies reported an early increase of TGFβ mRNA after radiation, with no difference 1 month later. 30, 42 We have also found a robust increase of TGFβ mRNA expression in adult murine cardiac fibroblasts 72 hours after radiation exposure, with no difference in the TGFβ expression in rat hearts 18 weeks after radiation. These data bring on an important concept of hit and run effects of ionizing radiation, in which initial hit triggers a fibro-inflammatory response and release of chronic mediators. In agreement, Krüse et al 42 also reported a peak increase of TGFβ mRNA at days 1 and 12 (maximum 6-fold of baseline), then returning to control levels by 1 month.
Conclusions and Therapeutic Implications
Although Ac-SDKP was found to have macrophage inhibitory and antifibrotic effects in some experimental models, there was a translational gap to transition these data into an effective therapy. To transition this peptide to the clinical arena, additional translational studies focused on the further evaluation of its pharmacodynamics and therapeutic efficacy will be required. However, we have provided the first direct evidence of cardioprotective effects of a novel endogenous peptide Ac-SDKP in radiation-induced cardiotoxicity.
